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Aims Heart failure with preserved ejection fraction (HFpEF) has a great epidemiological burden. The pathophysiological
role of cyclic guanosine monophosphate (cGMP) signalling has been intensively investigated in HFpEF. Elevated levels
of cGMP have been shown to exert cardioprotective effects in various cardiovascular diseases, including diabetic
cardiomyopathy. We investigated the effect of long-term preventive application of the phosphodiesterase-5A (PDE5A)
inhibitor vardenafil in diabetic cardiomyopathy-associated HFpEF.
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Methods
and results
Zucker diabetic fatty (ZDF) rats were used as a model of HFpEF and ZDF lean rats served as controls. Animals
received vehicle or 10mg/kg body weight vardenafil per os from weeks 7 to 32 of age. Cardiac function, morphology
was assessed by left ventricular (LV) pressure–volume analysis and echocardiography at week 32. Cardiomyocyte
force measurements were performed. The key markers of cGMP signalling, nitro-oxidative stress, apoptosis,
myocardial hypertrophy and fibrosis were examined. The ZDF animals showed diastolic dysfunction (increased
LV/cardiomyocyte stiffness, prolonged LV relaxation time), preserved systolic performance, decreased myocardial
cGMP level coupled with impaired protein kinase G (PKG) activity, increased nitro-oxidative stress, enhanced
cardiomyocyte apoptosis, and hypertrophic and fibrotic remodelling of the myocardium. Vardenafil effectively
prevented the development of HFpEF by maintaining diastolic function (decreased LV/cardiomyocyte stiffness and LV
relaxation time), by restoring cGMP levels and PKG activation, by lowering apoptosis and by alleviating nitro-oxidative
stress, myocardial hypertrophy and fibrotic remodelling.
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Conclusions We report that vardenafil successfully prevented the development of diabetes mellitus-associated HFpEF. Thus,
PDE5A inhibition as a preventive approach might be a promising option in the management of HFpEF patients with
diabetes mellitus.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
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Introduction
Heart failure (HF) is a complex clinical syndrome characterized by
specific clinical signs and symptoms and it is one of the most com-
mon causes leading to hospitalization.1 Three main forms of HF
are determined by the value of left ventricular (LV) ejection frac-
tion (EF) including HF with preserved EF (HFpEF; LVEF ≥50%).1 In
general, HFpEF is associated with diastolic dysfunction character-
ized by prolonged LV isovolumic relaxation, increased LV stiffness,
increased LV end-diastolic pressure and slow LV filling.2 To date, no
pharmacological treatment has been shown to effectively reduce
HFpEF-associated morbidity and mortality.1
Many diseases lead to the development of HF, such as atheroscle-
rosis, hypertension, cardiomyopathies, valvular diseases, arrhyth-
mias, etc.1 Furthermore, different co-morbidities such as diabetes
mellitus (DM) and obesity are often observed in HFpEF patients
and they play an important role in the progression and out-
come of HF.1,2 Therefore, the presence of these co-morbidities
must be taken into account in the prevention or treatment of
HFpEF.
Diabetic cardiomyopathy is a distinct disease entity that
develops in DM regardless of the presence of coronary
artery disease and hypertension.3 Several key processes can
be attributed to the development of diabetic cardiomyopathy
including myocardial fibrosis, hypertrophy, cardiac (mainly dias-
tolic) dysfunction, increased nitro-oxidative stress, apoptosis, and
inflammation.3
The nitric oxide (NO)–soluble guanylate cyclase (sGC)–cyclic
guanosine monophosphate (cGMP)–protein kinase G (PKG)
axis has been described as an important regulator of cardiac
contractility.4 In brief, under physiological conditions NO is pro-
duced by the endothelial cells and activates sGC as a gaseous
transmitter in its target cells such as cardiomyocytes and vas-
cular smooth muscle cells. In response to this, sGC produces
cGMP, the key regulator of the downstream effector PKG
enzyme.4 Essential regulators of this system are the phosphodi-
esterases (PDEs) as they are able to degrade cGMP to 5′-GMP.4
Phosphodiesterase-5A (PDE5A) is specific for cGMP molecules4
and has been described to be upregulated in different types of
HF and in diabetic cardiomyopathy in particular.5,6 Theoretically,
the above-mentioned upregulation of PDEs coupled with the
enhanced nitro-oxidative stress3 could notably contribute to the
impaired cGMP–PKG signalling in the myocardium of HFpEF
patients.7,8
Many pharmacological interventions have been proposed to
modulate NO signalling in the diabetic myocardium, including
PDE inhibitors.6 Vardenafil, a highly selective PDE5A inhibitor is
an on-demand treatment for erectile dysfunction and it displays
the highest potency compared with its comparators.9 Restora-
tion of the impaired cGMP signalling by the PDE5A inhibitor var-
denafil has been proven cardioprotective in different myocardial
pathologies.10–12
Based upon this, we investigated, in the present study, whether
long-term application of the PDE5A inhibitor vardenafil, started in
the prediabetic phase,13 could prevent the development of HFpEF
in an animal model of type 2 DM (T2DM). ..
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For details see the Supplementary material online, Methods S1.
Animals
The investigation conformed to the EU Directive 2010/63/EU
and the Guide for the Care and Use of Laboratory Animals used
by the US National Institutes of Health (NIH Publication No.
85–23, revised 1996). The experimental protocol was reviewed and
approved by the institutional ethics committee (permission number:
22.1/1162/3/2010). The Zucker diabetic fatty (ZDF) rat was used as
an animal model of HFpEF.14
Study protocol
Seven-week-old ZDF diabetic (fa/fa) and ZDF lean (+/?) rats (Charles
River, Sulzfeld, Germany) were randomized into four groups:
vehicle-treated controls (ZDFLean; n= 8), vardenafil-treated con-
trols (ZDFLean+Vard; n= 7), vehicle-treated diabetic (ZDF; n= 7),
and vardenafil-treated diabetic (ZDF+Vard; n= 8). Rats were fed
Purina #5008 diet (Charles River) and water ad libitum. Everyday per
os drug treatment [10mg/kg body weight (BW) vardenafil dissolved
in 0.01mol/L citrate buffer] or vehicle (0.01mol/L citrate buffer)
administration via drinking water was initiated at the age of 7week
and continued until the end of the experimental period. Functional
measurements were performed at the age of 32weeks. The BW of
the animals was measured every 2 days and the dose of vardenafil was
adjusted accordingly.
Echocardiography
Echocardiography was performed as described previously.15 The LV
anterior (AW) and posterior wall (PW) thicknesses and LV internal
diameter (ID) in end-diastole (d) and in end-systole (s) were measured
and relative wall thickness (RWT), LVmass, LVmass/tibia length (TL,
cm), LVmass index (LVmass/BW) were calculated.
Invasive haemodynamics
Invasive haemodynamic investigation was performed as described
earlier5 with a 2 F microtip pressure-conductance microcatheter
(SPR-838; Millar Instruments, Houston, TX, USA) system under
isoflurane anaesthesia (1–2%). Heart rate (HR), mean arterial blood
pressure (MAP), EF, cardiac output (CO), stroke work (SW), maximal
slope of systolic pressure increment (dP/dtmax) and diastolic pressure
decrement (dP/dtmin), time constant of LV pressure decay (TauW) were
calculated. The slope (Ees) of the LV end-systolic pressure–volume
relationships (ESPVR) and preload recruitable stroke work (PRSW)
were used as load-independent indices of contractility. The slope
of the LV end-diastolic pressure–volume relationship (EDPVR) was
determined as an index of LV diastolic stiffness. TL and heart weight
(HW, g) were measured.
Force measurement in permeabilized
left ventricular cardiomyocytes
Permeabilized rat LV cardiomyocytes were mounted in a mechan-
ical apparatus to measure isometric force and sarcomere length
(SL). Maximal active force (Fmax) was determined in the presence
© 2016 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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of a saturating Ca2+ concentration [pCa 4.75; pCa=−lg(Ca2+)], and
Ca2+-independent passive force (Fpassive) was measured in relaxing solu-
tion (pCa 9.0) during release–restretch manoeuvres. Both Fmax and
Fpassive were routinely recorded at a SL 2.3 μm, while Fpassive was also
registered for a range of SLs (between 1.9 μm and 2.5 μm).
Biochemistry
Blood glucose (BG) level was determined by a digital blood glucose
meter (Accu-Chek® Sensor; Roche, Mannheim, Germany). Plasma
cGMP was measured by using a cGMP enzyme immunoassay kit
(Amersham cGMP EIA Biotrak System; GE Healthcare, Chalfont St
Giles, UK). Plasma total nitrite/nitrate levels (NO bioavailability) were
determined by Nitric Oxide Colorimetric Assay Kit (#K262–200;
Biovision, Milpitas, CA, USA).
Quantitative real-time polymerase chain
reaction
LV mRNA samples were used for quantitative real-time polymerase
chain reaction (qRT-PCR) experiments. Myocardial hypertrophy
marker atrial natriuretic factor (ANF), fibrotic remodelling markers
fibronectin-1 (Fn1), collagen 1a1 (Col1a1) and 3a1 (Col3a1), markers
related to oxidative stress,16 such as catalase and thioredoxin-1
and sarcoplasmic reticulum calcium ATPase 2 (SERCA2a), phospho-
lamban (PLB) and PLB/SERCA2a ratios were investigated (see the
Supplementary material online, Table S1). Data were normalized to
glyceraldehyde-3-phosphate dehydrogenase (GAPDH).
Western blot
Western blot experiments were performed from LV samples. We
examined PDE5A, PKG, vasodilator-stimulated phosphoprotein
(VASP) and phospho-VASP (p-VASP) [p-VASP/VASP ratio (marker of
PKG activity)], cleaved caspase-3, total/cleaved poly (ADP-ribose) poly-
merase (PARP1), phospholamban (PLB), and phospho-phospholamban
(p-PLB) (see the Supplementary material online, Table S2). After
development, band densities were quantified and values were adjusted
to 𝛼-tubulin.
Histology and immunohistochemistry
Myocardial sections were deparaffinized and stained with haema-
toxylin and eosin (H&E), Masson’s trichrome (MT) or PicroSirius. Car-
diomyocyte diameter was measured as described previously.5 Fibrotic
remodelling was evaluated on MT and PicroSirius stained sections.
PicroSirius area was assessed on red, green and blue (RGB) stacked
images by thresholding with Image J (NIH, Bethesda, MD, USA).
Immunohistochemistry for 3-nitrotyrosine (3-NT) and cGMP were
also performed (see the Supplementary material online, Table S2).
Terminal deoxynucleotidyl transferase
dUTP nick-end labelling assay
Terminal deoxynucleotidyl transferase dUTP nick-end labelling
(TUNEL) assay (DeadEnd™ Colorimetric TUNEL System;
Promega, Mannheim, Germany) was performed to detect DNA
fragmentation. ..
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Data are presented as mean± SEM. Normal distribution was tested by
the Shapiro–Wilks method. Two-way analysis of variance (ANOVA)
with the factors ‘T2DM’ and ‘Vardenafil’ was performed (see the Sup-
plementary material online, Table S3). A Tukey honestly significant
difference (HSD) post hoc test was used to examine intergroup dif-
ferences. Pearson or Spearman test was used for correlation analysis
appropriately depending on data distribution. A P-value <0.05 was
deemed significant.
Results
Basic characteristics
The BW of the animals did not differ statistically at the end of
the study period (Table 1). Both ZDF and ZDF+Vard animals had
significantly elevated BG levels throughout the study period (see
the Supplementary material online, Figure S1).
Vardenafil prevented type 2 diabetes
mellitus-associated left ventricular
dysfunction in vivo
Neither HR nor MAP differed among the groups (Table 1). The
slope of EDPVR (LV stiffness parameter) and TauW showed signif-
icant increase in ZDF (Figure 1a,b). Vardenafil treatment markedly
improved the slope of EDPVR, while TauW tended to decrease
in ZDF rats (Figure 1b). Factorial ANOVA revealed significant dif-
ferences in EDPVR and TauW between T2DM and non-diabetic
animals (see the Supplementary material online, Table S3). Despite
the marked diastolic dysfunction in T2DM, conventional systolic
parameters, such as EF, CO, dP/dtmax, and SW did not differ among
our study groups (Table 1). Moreover, reliable load-independent
systolic parameters Ees and PRSW remained unchanged (Figure 1c).
Vardenafil prevented type 2 diabetes
mellitus-associated stiffening of LV
cardiomyocytes
The value of Fpassive (at different SLs; a marker of cardiomyocyte
stiffness) increased significantly in ZDF rats (Figure 1d). Vardenafil
prevented the diabetes-associated increase of Fpassive (Figure 1d),
however, it had no effect on Fmax (Figure 1e).
Vardenafil decreased myocardial
hypertrophy in Zucker Diabetic Fatty
rats
Although HW and HW/BW ratios were not different, HW/TL
ratio increased significantly in ZDF compared with ZDFLean rats
(Table 1). The HW/TL ratio of ZDF+Vard rats tended to decrease
compared with ZDF rats (Table 1). In addition, echocardiography
revealed signs of myocardial hypertrophy in ZDF rats, indicated by
the significantly elevated LVAW and LVPW in ‘s’ and ‘d’, increased
© 2016 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Table 1 Basic characteristics and haemodynamic parameters in the study groups
Variable ZDFLean ZDFLean+Vard ZDF ZDF+Vard
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Basic characteristics
BW (g) 421± 9 419±12 395± 25 405± 28
HW (g) 1.46± 0.03 1.55± 0.02 1.55± 0.03 1.51± 0.04
HW/BW (g/kg) 3.46± 0.05 3.71± 0.13 3.98± 0.25 3.79± 0.24
HW/TL (g/cm) 0.346± 0.007 0.364± 0.005 0.389± 0.007* 0.377± 0.010
Echocardiography†
LVAWs (mm) 2.53± 0.04 2.58± 0.15 2.90± 0.08* 2.48± 0.05#
LVAWd (mm) 1.73± 0.03 1.76± 0.03 1.88± 0.01* 1.72± 0.03#
LVIDs (mm) 4.91± 0.21 4.84± 0.16 4.50± 0.14 5.04± 0.19
LVIDd (mm) 8.08± 0.20 7.83± 0.15 7.99± 0.32 8.08± 0.29
LVPWs (mm) 2.63± 0.07 2.69± 0.10 3.07± 0.10* 2.93± 0.11
LVPWd (mm) 1.72± 0.08 1.91± 0.07 2.12± 0.10* 2.02± 0.10
RWT 0.41± 0.02 0.47± 0.01 0.50± 0.03* 0.47± 0.02
LVmass (g) 0.98± 0.02 1.01± 0.05 1.15± 0.05 1.09± 0.07
LVmass/TL (g/cm) 0.232± 0.005 0.245± 0.118 0.299± 0.010* 0.271± 0.017
LVmass index (g/kg BW) 2.53± 0.09 2.66± 0.13 3.23± 0.23* 2.99± 0.23
Haemodynamic parameters
HR (b.p.m.) 326± 4 327± 8 310± 6 319± 8
MAP (mmHg) 96± 3 96± 3 99± 2 105± 2
EF (%) 65± 2 66± 2 61± 2 64± 4
CO (mL/min) 67± 5 70± 5 55± 5 58± 9
dP/dtmax (mmHg/s) 9426± 453 9061± 270 8478± 234 9994± 634
dP/dtmin (mmHg/s) −9799± 549 −9706± 424 −9039± 639 −9463±1084
SW (mmHg.μL) 19378±1125 20567±1231 17279±1392 17848± 2576
BW, body weight; HW, heart weight, TL, tibia length; LV, left ventricular; AW, anterior wall thickness; PW, posterior wall thickness; LVID, LV internal diameter; RWT, relative
wall thickness; HR, heart rate; MAP, mean arterial pressure; EF, ejection fraction; CO, cardiac output; dP/dtmax and dP/dtmin, maximal and minimal slope of dP/dt; SW, stroke
work.
*P< 0.05 vs. ZDFLean; #P< 0.05 vs. ZDF.
†The ‘s’ and ‘d’ after the acronyms indicate end-systolic and end-diastolic, respectively.
RWT, LVmass/TL, and LVmass index (Table 1). All of these param-
eters tended to decline in ZDF+Vard rats, while LVAWs and
LVAWd were reduced markedly in response to vardenafil treat-
ment when compared with ZDF rats (Table 1). In addition to
the robust hypertrophy observed on echocardiography (Figure 1f ),
significant elevation of ANF (Figure 1g), histological evaluation of
H&E sections (Figure 1h) along with the robust increase in car-
diomyocyte diameter/TL (Figure 1i) supported cardiac hypertrophy.
Vardenafil significantly reduced the gene expression level of ANF
(Figure 1g) and decreased cardiomyocyte diameter/TL (Figure 1i).
The slope of EDPVR correlated robustly with the hypertrophy
marker cardiomyocyte diameter/TL (Figure 1j).
Vardenafil reduced alterations associated
with myocardial nitro-oxidative stress
in type 2 diabetes mellitus
Type 2 DM was associated with markedly elevated 3-NT content
of the left ventricle (Figure 2a,b), however, vardenafil preven-
tion effectively reduced it (Figure 2a,b). In accord with this, we
observed significant upregulation of different antioxidant enzymes,
including catalase and thiorexodin-1 in the ZDF group (Figure 2c).
Nevertheless, as a result of chronic drug treatment catalase and .
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.. thioredoxin-1 levels declined significantly in ZDF rats (Figure 2C).
Moreover, SERCA2a was markedly downregulated in ZDF rats
regardless of treatment (Figure 2d). The PLB gene expression
tended to decrease in the ZDF group (Fig.2D), although, in the
ZDF+Vard group, it did not show any difference when compared
with the ZDFLean group (Figure 2d). Despite the unchanged PLB/
SERCA2a ratio in T2DM (Figure 2d), vardenafil treatment markedly
increased the ratio of PLB/SERCA2a in ZDF animals (Figure 2c).
Vardenafil suppressed myocardial fibrotic
remodelling in type 2 diabetes mellitus
Masson trichrome and PicroSirius staining revealed fibrotic remod-
elling of the myocardium in ZDF (Figure 3a–d), the extent of
which correlated robustly with the slope of EDPVR (Figure 3e).
Fibronectin-1 was markedly overexpressed in T2DM (Figure 3f ).
Both Col1a1 and Col3a1 mRNAs were also significantly downreg-
ulated in ZDF rats (Figure 3g). Prevention by vardenafil effectively
reduced the fibrotic remodelling of the myocardium (Figure 3a-d)
and significantly reduced Fn1 gene expression (Figure 3f ) in T2DM.
Interestingly, Col1a1 and Col3a1 gene expressions were unaltered
by vardenafil in the ZDF+Vard group compared with the ZDF
group (Figure 3g).
© 2016 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Figure 1 The effect of vardenafil on the haemodynamic alterations and on myocardial hypertrophy in heart failure with preserved ejection
fraction animals. (a) Representative left ventricular (LV) pressure–volume (P-V) loops. The arrow indicates the increase of the slope of
end-diastolic pressure–volume relationship (EDPVR). (b) Graphs represent the value of the slope of (EDPVR) and TauW. (c) Graphs of the
slope (Ees) of the LV end-systolic P-V relationship and the value of preload-recruitable stroke work (PRSW). (d) Fpassive (cardiomyocyte stiffness
marker) at different sarcomere lengths. (e) Fmax in the study groups. (f) Representative M-mode echocardiography images at the mid-papillary
level on short axis view. (g) Relative gene expression of atrial natriuretic factor (ANF). (h) Representative haematoxylin-eosin stained sections.
Bar: 50 μm, Magnification: 200×. (i) Quantification of cardiomyocyte diameter/tibia length (TL). (j) Correlation analysis between cardiomyocyte
diameter/tibia length (TL) and the slope of EDPVR. Study groups are defined in the text. *P< 0.05 vs. ZDFLean; #P< 0.05 vs. ZDF.
Phosphodiesterase-5A inhibition
prevented cardiomyocyte apoptosis
in Zucker Diabetic Fatty rats
Evidence for increased cardiomyocyte apoptosis was shown
by TUNEL assay (Figure 4a,b), and demonstrated by markedly .
..
..
..
..
..
..
..
..
.. risen cleaved caspase-3 and cleaved PARP1 band densities
(Figure 4c,d). However, vardenafil prevented the above alter-
ations by significantly decreasing the number of TUNEL-positive
nuclei (Figure 4b) and cleaved PARP1 band density (Figure 4d).
Cleaved caspase-3 band density was not significantly differ-
ent in ZDF+Vard group compared with the ZDFLean group
(Figure 4c).
© 2016 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Figure 2 Phosphodiesterase-5A inhibition reduces the extent of cardiac nitro-oxidative stress in heart failure with preserved ejection fraction.
(a) Representative images of 3-nitrotyrosine (3-NT) stained sections. Arrows indicate the grey coloured 3-NT positive area. Bar: 50 μm,
Magnification: 200×. (b) Quantification of 3-NT positive area in the experimental groups. (c) Relative gene expression levels of catalase and
thioredoxin-1. (d) Gene expression levels of sarcoplasmic reticulum calcium ATPase 2 (SERCA2a), phospholamban (PLB) and the ratio of
PLB/SERCA2a are shown. A detailed description of the study groups is available in the text. *P< 0.05 vs. ZDFLean; #P< 0.05 vs. ZDF.
Vardenafil prevented the disturbances
of myocardial cyclic guanosine
monophosphate–protein kinase G
signalling in Zucker Diabetic Fatty rats
The PDE5A–cGMP–PKG axis significantly deteriorated in T2DM,
as demonstrated by the markedly lower cGMP staining intensity
of the myocardium (Figure 5a,b), by the increased protein levels
of PDE5A and PKG (Figure 5d) and by the lower p-VASP/VASP
ratio (as a marker of impaired PKG activity; Figure 5d). Myocardial
PDE5A levels in the ZDF+Vard group did not differ from the
healthy controls (Figure 5d). Vardenafil effectively increased the
cGMP staining intensity of the ZDF group myocardium (Figure 5a,b).
Furthermore, vardenafil elevated the plasma cGMP content in ZDF
rats (Figure 5c) and restored the ratio of p-VASP/VASP (Figure 5d).
Interestingly, the plasma cGMP level showed a strong tendency
toward elevation in ZDFLean+Vard group (Figure 5d). Plasma total
nitrite/nitrate levels and p-PLB/PLB ratios were not different among
the groups (see the Supplementary material online, Figure S2).
Discussion
The main findings of the present study are that PDE5A inhibi-
tion with long-term vardenafil application (i) effectively prevents
the development of HFpEF (characterized by increased myocardial
stiffness and worsened diastolic function), (ii) reduces the patho-
physiological features of T2DM-associated diabetic cardiomyopa-
thy, and (iii) restores the activity of cGMP–PKG axis by increasing
myocardial as well as plasma cGMP levels.
Heart failure with preserved EF is characterized by the clini-
cal signs of HF, however, cardiac systolic function measured by EF .
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. is preserved (LVEF ≥50%) with a concomitant decrease in dias-
tolic function (increased stiffness, decreased relaxation and slow
LV filling).1,2 The importance of co-morbidities and the subsequent
deterioration of the NO-cGMP-PKG signalling has been proposed
in the development of HFpEF by Paulus and Tschope.8 The pres-
ence of co-morbidities (especially obesity and T2DM) leads to an
increased level of reactive oxygen species (ROS), decreased NO
bioavailability, and lower cGMP levels, with subsequent deactiva-
tion of the main effector, PKG enzyme. In line with this finding,
van Heerebeek et al.7 found lower myocardial PKG activity in the
myocardium of HFpEF patients.
The restoration of NO-cGMP-PKG axis has been proven to be
cytoprotective in different cardiovascular diseases6,17,18 including
diabetic cardiomyopathy.5,6,12 Phosphodiesterase-5A inhibitors
block one of the main regulator of cGMP degradation thereby pre-
serving and/or increasing intracellular cGMP concentration.4 The-
oretically, blocking the PDE5A in pathological LV remodelling could
provide a useful tool in the management of HF patients. The above
idea led to a clinical trial investigating the cardioprotective effects of
sildenafil in HFpEF patients (RELAX study).19 Despite the promis-
ing preclinical data, sildenafil showed no improvements in exercise
capacity or on the clinical outcomes in advanced HFpEF patients.19
However, cGMP plasma levels were not significantly different at the
end of the study period between the study groups. In light of this,
one can speculate that PDE5A inhibition might have been ineffective
and it could have contributed to the negative results.19 The above
data suggest that improving cGMP signalling is a promising avenue
of research; however, the result of the RELAX trial raises impor-
tant questions about the appropriate pharmacological approach.
In line with this, Franssen and Gonzalez Miqueo20 reported that
the initial phase of HFpEF is presumably predominated by the
© 2016 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Figure 3 Protective effects of vardenafil on myocardial fibrosis in heart failure with preserved ejection fraction. (a) Representative images
and (b) semiquantitative scoring of Masson’s trichrome stained sections. Arrows indicate interstitial fibrosis of the myocardium. Bar: 50 μm,
Magnification: 200×. (c) Representative images and (d) quantification of PicroSirius stained myocardium. Bar: 50 μm, Magnification: 200×.
(e) Correlation analysis between PicroSirius positive area and the slope of end-diastolic pressure–volume relationship (EDPVR). (f) Gene
expression of fibronectin-1 (Fn1), (g) collagen 1a1 and 3a1 (Col1a1; Col3a1). A detailed description of the study groups is available in the text.
*P< 0.05 vs. ZDFLean; #P< 0.05 vs. ZDF
© 2016 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Figure 4 The effects of vardenafil on myocardial DNA fragmentation and apoptosis. (a) Representative images of terminal deoxynucleotidyl
transferase dUTP nick-end labelling (TUNEL) assay. Bar: 50 μm, Magnification: 200×. (b) Quantification of TUNEL positive nuclei/field. (c)
Graphs and representative western blot bands of cleaved caspase-3 (17 kDa) and (d) cleaved poly (ADP-ribose) polymerase (PARP1; 85 kDa)
levels in the myocardium. A detailed description of the study groups is available in the text. *P< 0.05 vs. ZDFLean; #P< 0.05 vs. ZDF.
dysfunction of cardiomyocytes, thus it could be useful to improve
cGMP signalling to reduce cardiomyocyte stiffness. In contrast,
sildenafil has been shown to exert anti-remodelling effect in T2DM
diabetic cardiomyopathy in humans.21 Moreover, Koka et al.22
showed beneficial effects of tadalafil on systolic performance and
mitochondrial function in db/db mice. Nevertheless, they did not
report how PDE5A inhibitors affect diastolic dysfunction in T2DM.
Accordingly, we believe that instead of treating the already
developed HFpEF, effective pharmacological prevention by PDE5A
inhibitors might be more appropriate in the management of HFpEF
patients with co-morbidities such as obesity and DM. Thus, in
the present study, we investigated the effects of PDE5A inhi-
bition in a preventive manner (from the pre-diabetic state) on
the development of HFpEF (mainly on diastolic function) in the
ZDF rat.
Several studies have focused on the investigation of cardiac func-
tion in HFpEF. Previous data showed that diastolic dysfunction can
be determined in the HFpEF animal model ZDF rat.23,24 In accord
with the literature we observed a significant increase in LV stiff-
ness and prolonged relaxation time by pressure–volume analysis
in our model. In addition, cardiomyocyte stiffness (as shown by
increased Fpassive) was also evident in T2DM. However, in vivo and
in vitro systolic performance was preserved, fulfilling the criteria for
HFpEF in ZDF rats. Interestingly, we did not observe any difference .
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. in HR and MAP. Vardenafil effectively prevented diastolic dysfunc-
tion both in vivo (decreased LV stiffness, improved relaxation time)
and at the sarcomeric level (decreased cardiomyocyte Fpassive) in
ZDF rats. Hypophosphorylation of the PEVK-domain of titin might
play a role in the observed phenomena.25
We found lower myocardial cGMP level coupled with increased
protein expression of PDE5A (a possible contributor to the low
myocardial cGMP content) and PKG enzymes in the heart of
HFpEF animals. Although PKG protein levels were increased, PKG
activity (as reflected by the p-VASP/VASP ratio) showed significant
impairment in the diabetic myocardium. Interestingly, plasma cGMP
levels remained unchanged in ZDF. One can speculate that this
might be a consequence of the observed compensatory upregula-
tion of ANF and subsequent activation of particulate GC in other
organs. Thus preserved plasma cGMP is seen as a sign of overspill
of cGMP from different tissues.5 Vardenafil effectively restored the
activity of the cGMP–PKG axis, as shown by increased plasma/
cardiac cGMP concentrations and p-VASP/VASP ratio.
Pathological remodelling of the myocardium in diabetic car-
diomyopathy is a well-known phenomenon and is character-
ized by fibrosis, hypertrophy, increased nitro-oxidative stress, and
cardiomyocyte apoptosis.3 Hyperglycaemia can directly lead to
the accumulation of ROS and to the development of severe
nitro-oxidative stress in DM.3 Several mechanisms have been
© 2016 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Figure 5 Modulatory effects of vardenafil on the myocardial NO-cGMP signalling in T2DM. (a) Representative images. Bar: 50 μm,
Magnification: 200×. (b) Quantification of cGMP immunohistochemistry in the study groups. (c) Plasma cGMP levels in the experimental
groups. (d) Graphs and representative western blot bands of phosphodiesterase-5A (PDE5A, 130 kDa), protein kinase G (PKG, 75 kDa) and
phospho-vasodilator-stimulated phosphoprotein (p-VASP) and VASP (50 kDa) are shown. A detailed description of the study groups is available
in the text. *P< 0.05 vs. ZDFLean; #P< 0.05 vs. ZDF.
described to play a decisive role in DM-associated nitro-oxidative
stress such as the upregulation of NADPH-oxidases and NO
synthases.3 Moreover, in nitro-oxidative stress peroxynitrite is gen-
erated when ROS directly reacts with NO thus it contributes
to the decreased NO bioavailability.26 Peroxynitrite is a highly
reactive molecule that directly deteriorates different cellular ele-
ments, enzymes, myofibrillar proteins, and DNA.26 In agreement
with this, we observed hyperglycaemia at an early age which
increased gradually during the study. We also found increased
nitro-oxidative stress as well as an upregulation of the different
antioxidant enzymes in the LV myocardium of ZDF animals. How-
ever, plasma nitrite/nitrate levels (reflecting NO bioavailability)
were not diminished. In addition, SERCA2a gene expression was
significantly lower, which might reflect the disturbance of intracellu-
lar Ca2+ homeostasis and could contribute to the prolonged relax-
ation time in T2DM.27 Vardenafil, however, significantly affected the
DM-associated nitro-oxidative stress as it prevented an increase
of 3-NT staining and the elevation of catalase and thioredoxin-1
in the ZDF group myocardium. The protective feature of PDE5A
inhibition is probably attributed to its antioxidative effects28 and to .
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.. the enhancement of cGMP signalling.12 Moreover, vardenafil signif-
icantly increased the ratio of PLB/SERCA2a gene expression which
might have contributed to the observed improved diastolic function
in the ZDF+Vard group.
Not only peroxynitrite but ROS also directly propagates
DNA fragmentation and apoptosis in DM leading to the loss of
cardiomyocytes.5,26 In addition to the increased rate of apopto-
sis, several pathological processes play role in the development
of myocardium hypertrophy and fibrosis (both interstitial and
replacement types), including the dysregulation of the transform-
ing growth factor 𝛽 (TGF-𝛽) signalling,3,5 fibroblast proliferation,3
and disturbance of the matrix metalloproteinases (MMPs).29
Corresponding to this, our DM model developed HFpEF char-
acterized by increased apoptosis. Moreover, our experiments
revealed massive cardiac hypertrophy not only by echocardiog-
raphy but also by the post-mortem analysis of the myocardium
(increased HW/TL, cardiomyocyte diameter/TL, and ANF gene
expression). In addition to the development of concentric hyper-
trophy, fibrotic remodelling was present in the left ventricle of
our ZDF animals (higher MT score, PicroSirius area and Fn1 gene
© 2016 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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expression). Interestingly, Col1a1 and Col3a1 mRNA levels were
significantly reduced in T2DM; however, in agreement with data
in the literature,5,29 this might be the consequence of a negative
feedback mechanism. Through the improved cGMP signalling,
vardenafil effectively reduced myocardial apoptosis (via the inhi-
bition of PARP cleavage), cardiomyocyte hypertrophy, and fibrotic
remodelling of the myocardium. Our results are in line with the
data of previous studies that reported antihypertrophic effects
of the enhancement of cGMP signalling.5,30 In the background of
improved fibrosis a regulatory cross-talk between the enhanced
PKG signalling and the key members of cardiac remodelling such
as TGF-𝛽 signalling,5,12 microvascular inflammation, endothelin-1,
angiotensin II, and aldosterone8 can be assumed. It is notable
that diastolic dysfunction (slope of EDPVR) correlated with both
cardiac hypertrophy and fibrosis. Although many contributing
factors have been identified in the progression of HFpEF, we
still lack a treatment for proper patient management. A signifi-
cant point of intervention might be to improve the myocardial
NO-cGMP-PKG signalling. However, from previous clinical trials it
seems rather that a pharmacological prevention could contribute
significantly to the improvement of HFpEF. To our knowledge,
this is the first study reporting the preventive cardioprotective
effects of vardenafil on diastolic function in an animal model of
HFpEF. The presence of co-morbidities in HFpEF patients has
to be taken into account when planning the pharmacological
management of patients. In agreement with this, early initiated
pharmacological prevention with the PDE5A inhibitor varde-
nafil might be a therapeutic alternative for patients with DM
and HFpEF.
Study limitations
Our study is limited to young, male rats. Although the
p-VASP/VASP ratio was considered as a marker to estimate
PKG activity, direct measurement of PKG activity is the gold stan-
dard method as VASP phosphorylation could also be influenced
by other PKs. Involvement of cGMP–cAMP crosstalk and PKA
activation as a subsidiary mechanism in the observed effects of
vardenafil cannot be ruled out. Our present work focused on the
effects of preventive therapy by vardenafil in T2DM. However,
the determination of the optimal time-point of the pharma-
ceutical intervention might be an important aspect of future
investigations.
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